Use of pegylated interferon in hypereosinophilic syndrome

Joseph H. Butterfield, Catherine R. Weiler

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

Original languageEnglish (US)
Pages (from-to)192-197
Number of pages6
JournalLeukemia Research
Volume36
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Hypereosinophilic Syndrome
Interferons
interferon alfa-2b
Lymphopenia
Alopecia
Eosinophilia
Neutropenia
Interferon-alpha
Chromosome Aberrations
Liver
Enzymes
Therapeutics

Keywords

  • Eosinophilia
  • Hypereosinophilic syndrome
  • Immunoglobulins
  • Interferon
  • Methoxy polyethylene glycol

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Use of pegylated interferon in hypereosinophilic syndrome. / Butterfield, Joseph H.; Weiler, Catherine R.

In: Leukemia Research, Vol. 36, No. 2, 02.2012, p. 192-197.

Research output: Contribution to journalArticle

Butterfield, Joseph H. ; Weiler, Catherine R. / Use of pegylated interferon in hypereosinophilic syndrome. In: Leukemia Research. 2012 ; Vol. 36, No. 2. pp. 192-197.
@article{b3a8a45f8b664a98a6e4614aa7989b12,
title = "Use of pegylated interferon in hypereosinophilic syndrome",
abstract = "Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.",
keywords = "Eosinophilia, Hypereosinophilic syndrome, Immunoglobulins, Interferon, Methoxy polyethylene glycol",
author = "Butterfield, {Joseph H.} and Weiler, {Catherine R.}",
year = "2012",
month = "2",
doi = "10.1016/j.leukres.2011.09.026",
language = "English (US)",
volume = "36",
pages = "192--197",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Use of pegylated interferon in hypereosinophilic syndrome

AU - Butterfield, Joseph H.

AU - Weiler, Catherine R.

PY - 2012/2

Y1 - 2012/2

N2 - Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

AB - Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

KW - Eosinophilia

KW - Hypereosinophilic syndrome

KW - Immunoglobulins

KW - Interferon

KW - Methoxy polyethylene glycol

UR - http://www.scopus.com/inward/record.url?scp=84855188876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855188876&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.09.026

DO - 10.1016/j.leukres.2011.09.026

M3 - Article

C2 - 22118911

AN - SCOPUS:84855188876

VL - 36

SP - 192

EP - 197

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -